CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for RXElite Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

RXElite Inc
1404 N Main St Ste 200
Phone: (208) 288-5550p:208 288-5550 MERIDIAN, ID  83642-2828  United States Ticker: RXEI RXEI
This company ceased filing statements with the SEC on 2/3/2009.
Business Summary
RxElite, Inc. (RxElite) develops and markets generic prescription drug products in specialty generic markets. RxElite's markets and pipeline products are in specialty markets. These markets include specialty products in the areas of anesthesia gases, sterile liquid dose products, which includes ophthalmic products, sterile inhalation respiratory products and injectable, drugs and active pharmaceutical ingredients (APIs). The Company's customers include hospitals and hospital group purchasing organizations, national and regional wholesalers, direct retail pharmacy stocking chains, homecare companies, and outpatient surgery centers and ambulatory care clinics. In January 2008, RxElite acquired FineTech Laboratories, Ltd, which manufactures APIs in its facility in Haifa, Israel. In January 2009, RXElite announced the sale of all the issued and outstanding capital stock of RxElite Holdings Inc. (Holdings), its wholly owned United States subsidiary, to Piramal Healthcare Limited.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/200812/31/2007YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
7371 Computer programming services

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Peter W.Williams 74 9/20/2007 7/13/2007
President, Chief Executive Officer EarlSullivan 40 11/21/2008 7/13/2007
Senior Vice President - New Business Development RickSchindewolf 50 1/21/2008 1/21/2008
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Cendian Pharmaceuticals Ltd.
FineTech Laboratories Ltd.
RXEI
4 additional Business Names available in full report.

General Information
Number of Employees: 47 (As of 3/17/2008)
Outstanding Shares: 119,705,157 (As of 9/30/2008)
Shareholders: 300
Stock Exchange: OTC
Federal Tax Id: 900366910
Fax Number: (302) 636-5454


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, August 29, 2023